中國廣核(003816.SZ):陸豐1號及2號等核電機組建設獲得核准
格隆匯8月19日丨中國廣核(003816.SZ)公佈,2024年8月19日,公司獲悉公司的子公司山東招遠核電有限公司的招遠1號及2號機組、中廣核陸豐核電有限公司的陸豐1號及2號機組,和公司控股股東委託本公司管理的中廣核蒼南第二核電有限公司的蒼南3號及4號機組已獲得國務院核准。目前本公司及上述各公司正在有序地開展上述機組各項施工準備工作,在取得國家核安全局頒發的《核電廠建造許可證》後,即可開始全面建設。
本次核准的陸豐1號及2號機組的單台機組容量為1,245MW,招遠1號及2號機組的單台機組容量為1,214MW,蒼南3號及4號機組的單台機組容量為1,215MW。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.